Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge

Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thrombosis and haemostasis Ročník 120; číslo 6; s. 949 - 956
Hlavní autoři: Violi, Francesco, Pastori, Daniele, Cangemi, Roberto, Pignatelli, Pasquale, Loffredo, Lorenzo
Médium: Journal Article
Jazyk:angličtina
Vydáno: Stuttgart · New York Georg Thieme Verlag KG 01.06.2020
Témata:
Algorithms
Betacoronavirus
Cardiology
Coronavirus Infections - blood
Coronavirus Infections - complications
COVID-19
Fibrin Fibrinogen Degradation Products - analysis
Fibrinolytic Agents - therapeutic use
Humans
Liver Failure - therapy
Pandemics
Partial Thromboplastin Time
Platelet Count
Pneumonia, Viral - blood
Pneumonia, Viral - complications
Prothrombin Time
Review Article
Risk
SARS-CoV-2
Thrombophilia - prevention & control
Thrombophilia - therapy
Thrombosis - prevention & control
Thrombosis - therapy
Treatment Outcome
hypercoagulability
thrombosis
infectious diseases
ISSN:0340-6245, 2567-689X, 2567-689X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment.
AbstractList The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment.
Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment.
The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment.The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment.
Author Pastori, Daniele
Violi, Francesco
Cangemi, Roberto
Pignatelli, Pasquale
Loffredo, Lorenzo
Author_xml – sequence: 1
  givenname: Francesco
  surname: Violi
  fullname: Violi, Francesco
  email: francesco.violi@uniroma1.it
  organization: I Clinica Medica, Sapienza University of Rome
– sequence: 2
  givenname: Daniele
  surname: Pastori
  fullname: Pastori, Daniele
  organization: Department of Clinical, Internal Medicine, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy
– sequence: 3
  givenname: Roberto
  surname: Cangemi
  fullname: Cangemi, Roberto
  organization: Department of Translational and Precision Medicine, Sapienza University of Rome, Italy
– sequence: 4
  givenname: Pasquale
  surname: Pignatelli
  fullname: Pignatelli, Pasquale
  organization: Department of Clinical, Internal Medicine, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy
– sequence: 5
  givenname: Lorenzo
  orcidid: 0000-0002-6542-6235
  surname: Loffredo
  fullname: Loffredo, Lorenzo
  organization: Department of Clinical, Internal Medicine, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32349133$$D View this record in MEDLINE/PubMed
BookMark eNo1kMFLwzAYxYMouk2vHiVHL9V8TdI23sZQJ4iCTPAW0vSrq7TJTFLF_94N5-kd3o_H4zclh847JOQc2BUwKa9jxphgGZTAOJQHZJLLosyKSr0dkgnj26rIhTwh0xg_GINCKHlMTnjOhQLOJ-Rl-bPBYL15H3uTOu-ocQ2du9SldfBD7VNn6SqgSQO6RDtHFz54Z766MEaaM1A3dE6f8Jsu1qbv0b3jKTlqTR_xbJ8z8np3u1oss8fn-4fF_DGzQomUNa20phUKsRCV4W3DRW2booXCltAK23CrapMzCaIVXMoGAFqExkClVMmRz8jl3-4m-M8RY9JDFy32vXHox6hzropKCinFFr3Yo2M9YKM3oRtM-NH_HrZA9gekdYcD6g8_Brc9r4HpnWcd9c6z3nvmv0aUbsk
CitedBy_id crossref_primary_10_3889_oamjms_2021_7455
crossref_primary_10_3390_ijerph17207371
crossref_primary_10_1055_s_0040_1715798
crossref_primary_10_25259_SNI_898_2022
crossref_primary_10_3390_ijms24043169
crossref_primary_10_3390_ijms21218141
crossref_primary_10_1111_eci_13436
crossref_primary_10_1177_1076029620944497
crossref_primary_10_1016_j_avsg_2021_01_072
crossref_primary_10_3390_v15061385
crossref_primary_10_1016_j_avsg_2022_04_048
crossref_primary_10_3889_oamjms_2022_10886
crossref_primary_10_1080_13625187_2020_1850678
crossref_primary_10_1055_a_2595_5458
crossref_primary_10_3390_ijms26146854
crossref_primary_10_3390_nu14071390
crossref_primary_10_7759_cureus_19757
crossref_primary_10_3390_diagnostics11061114
crossref_primary_10_5662_wjm_v14_i3_92983
crossref_primary_10_3389_fcvm_2020_00151
crossref_primary_10_1016_j_compbiomed_2025_110502
crossref_primary_10_1016_j_cyto_2024_156503
crossref_primary_10_1177_10760296241254104
crossref_primary_10_1055_s_0040_1718532
crossref_primary_10_3390_ijms231710106
crossref_primary_10_3389_fcvm_2022_901245
crossref_primary_10_1007_s11239_021_02385_8
crossref_primary_10_1007_s11940_022_00713_8
crossref_primary_10_2478_arsm_2023_0008
crossref_primary_10_4103_jrms_JRMS_1213_20
crossref_primary_10_1155_2022_7325060
crossref_primary_10_1016_j_amjoto_2020_102746
crossref_primary_10_1097_NRL_0000000000000403
crossref_primary_10_1111_eci_13378
crossref_primary_10_1016_j_thromres_2022_06_014
crossref_primary_10_1159_000521808
crossref_primary_10_1183_23120541_00644_2022
crossref_primary_10_1016_j_ebiom_2021_103228
crossref_primary_10_3390_neurolint13030041
crossref_primary_10_3390_clinpract12030028
crossref_primary_10_1002_jmv_26856
crossref_primary_10_1159_000514155
crossref_primary_10_17116_kardio202316031267
crossref_primary_10_1055_s_0040_1722308
crossref_primary_10_2147_VHRM_S276530
crossref_primary_10_1055_s_0042_1760264
crossref_primary_10_1007_s10072_020_04486_3
crossref_primary_10_1016_j_wneu_2020_05_237
crossref_primary_10_1111_febs_15784
crossref_primary_10_1016_j_mehy_2020_110282
crossref_primary_10_17116_kardio202316021223
crossref_primary_10_1016_j_intimp_2020_107156
crossref_primary_10_3390_jcm10153349
crossref_primary_10_3390_jcm10143015
crossref_primary_10_1093_pcmedi_pbaa017
crossref_primary_10_3390_pharmaceutics13030431
crossref_primary_10_1055_a_1692_9939
crossref_primary_10_1097_MD_0000000000024002
crossref_primary_10_1007_s11940_025_00824_y
crossref_primary_10_1016_j_jcot_2020_11_018
crossref_primary_10_1097_CRD_0000000000000340
crossref_primary_10_3389_fneur_2023_1216978
crossref_primary_10_1016_j_numecd_2021_06_003
crossref_primary_10_1007_s11739_020_02621_8
crossref_primary_10_1161_CIRCRESAHA_122_321541
crossref_primary_10_1093_eurheartj_suab118
crossref_primary_10_1007_s13659_020_00271_z
crossref_primary_10_1007_s11739_023_03196_w
crossref_primary_10_23736_S0021_9509_21_12017_8
crossref_primary_10_3389_fneur_2020_571996
crossref_primary_10_1159_000510178
crossref_primary_10_1016_j_thromres_2020_08_043
crossref_primary_10_5937_afmnai40_41219
crossref_primary_10_3389_fnut_2021_739216
crossref_primary_10_1136_neurintsurg_2020_016794
crossref_primary_10_1007_s11739_020_02553_3
crossref_primary_10_1055_s_0040_1721486
crossref_primary_10_1111_ijcp_14426
crossref_primary_10_1007_s00415_020_09990_2
crossref_primary_10_1186_s13020_020_00360_8
crossref_primary_10_3390_v16010082
crossref_primary_10_1177_11795468211010705
crossref_primary_10_1055_s_0040_1722171
crossref_primary_10_17116_jnevro202312303276
crossref_primary_10_1055_s_0040_1718735
crossref_primary_10_1111_ene_14535
crossref_primary_10_3390_jcm11040948
crossref_primary_10_3390_jcm9113482
crossref_primary_10_1007_s11739_021_02880_z
crossref_primary_10_1016_j_heliyon_2024_e31380
crossref_primary_10_1055_s_0040_1714370
crossref_primary_10_1111_ijlh_13346
crossref_primary_10_1080_00207454_2022_2056460
crossref_primary_10_1097_NRL_0000000000000311
crossref_primary_10_1007_s10072_021_05299_8
crossref_primary_10_3389_fimmu_2021_574425
crossref_primary_10_1038_s41467_020_19996_z
crossref_primary_10_21697_ejohp_0702_05
crossref_primary_10_1080_09537104_2021_1936478
crossref_primary_10_1055_s_0040_1718729
crossref_primary_10_1016_j_jstrokecerebrovasdis_2022_106716
crossref_primary_10_1016_j_thromres_2021_06_014
crossref_primary_10_1002_brb3_2185
crossref_primary_10_1186_s12933_021_01368_6
crossref_primary_10_4103_aca_aca_237_20
crossref_primary_10_1007_s11739_020_02432_x
crossref_primary_10_1055_s_0040_1716543
crossref_primary_10_1080_20009666_2021_1933715
crossref_primary_10_1182_blood_2020008762
crossref_primary_10_1055_s_0040_1721778
crossref_primary_10_1055_a_1788_7592
crossref_primary_10_1089_ars_2020_8142
crossref_primary_10_3389_fneur_2020_584734
crossref_primary_10_1177_0267659120954386
crossref_primary_10_3390_healthcare10101838
crossref_primary_10_1097_MD_0000000000038423
crossref_primary_10_3390_pathogens10030370
crossref_primary_10_1007_s11739_022_02997_9
crossref_primary_10_1371_journal_ppat_1010118
crossref_primary_10_3390_biom11111558
crossref_primary_10_3389_fphar_2021_698008
crossref_primary_10_61751_bmbr_2_2024_66
crossref_primary_10_1038_s41375_020_0887_9
crossref_primary_10_1177_1076029620952884
crossref_primary_10_3389_fendo_2021_772865
crossref_primary_10_1080_10255842_2022_2124858
crossref_primary_10_1002_prp2_631
crossref_primary_10_1016_j_ejvs_2021_03_017
crossref_primary_10_31146_1682_8658_ecg_230_10_236_240
crossref_primary_10_1186_s10020_025_01227_0
crossref_primary_10_1055_s_0040_1721664
crossref_primary_10_1089_jir_2022_0061
crossref_primary_10_1007_s11886_022_01759_5
crossref_primary_10_1016_j_wneu_2020_07_158
crossref_primary_10_4330_wjc_v13_i10_556
crossref_primary_10_1007_s42399_023_01420_4
crossref_primary_10_3390_biomedicines11051241
crossref_primary_10_1007_s00011_021_01473_y
crossref_primary_10_1007_s15010_021_01658_x
crossref_primary_10_1016_j_jneuroim_2020_577436
crossref_primary_10_1038_s41423_022_00905_x
crossref_primary_10_3390_medicina58111554
crossref_primary_10_1055_s_0040_1715836
ContentType Journal Article
Copyright Georg Thieme Verlag KG Stuttgart · New York.
Copyright_xml – notice: Georg Thieme Verlag KG Stuttgart · New York.
DBID 0U6
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1055/s-0040-1710317
DatabaseName Thieme Connect Journals Open Access
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 0U6
  name: Thieme Connect Journals Open Access
  url: http://open.thieme.com
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2567-689X
EndPage 956
ExternalDocumentID 32349133
10_1055_s_0040_1710317
Genre Systematic Review
Journal Article
GroupedDBID ---
.55
.GJ
0R~
0U6
0VX
123
1KJ
4.4
53G
5RE
AAQQT
ABJNI
ABOCM
ACGFO
ACGFS
AENEX
AFFNX
AHRSK
ALMA_UNASSIGNED_HOLDINGS
BR6
C45
CS3
DU5
EBS
EJD
F5P
H13
J5H
OVD
P2P
RTC
RTE
SJN
TEORI
X7M
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c494t-df5caf49ee648a3fd34bcd6f16c71f4cd3c9ba20514f4355d111fe1da189973e3
IEDL.DBID 0U6
ISICitedReferencesCount 157
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000538130700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0340-6245
2567-689X
IngestDate Fri Jul 11 06:42:21 EDT 2025
Thu Jan 02 22:59:27 EST 2025
Sun Nov 24 14:58:07 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords hypercoagulability
thrombosis
infectious diseases
Language English
License Georg Thieme Verlag KG Stuttgart · New York.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c494t-df5caf49ee648a3fd34bcd6f16c71f4cd3c9ba20514f4355d111fe1da189973e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-6542-6235
OpenAccessLink http://dx.doi.org/10.1055/s-0040-1710317
PMID 32349133
PQID 2396854554
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_2396854554
pubmed_primary_32349133
thieme_journals_10_1055_s_0040_1710317
PublicationCentury 2000
PublicationDate 2020-06-01
PublicationDateYYYYMMDD 2020-06-01
PublicationDate_xml – month: 06
  year: 2020
  text: 2020-06-01
  day: 01
PublicationDecade 2020
PublicationPlace Stuttgart · New York
PublicationPlace_xml – name: Stuttgart · New York
– name: Germany
PublicationTitle Thrombosis and haemostasis
PublicationTitleAlternate Thromb Haemost
PublicationYear 2020
Publisher Georg Thieme Verlag KG
Publisher_xml – name: Georg Thieme Verlag KG
SSID ssj0016495
Score 2.660341
SecondaryResourceType review_article
Snippet Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is...
The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a...
SourceID proquest
pubmed
thieme
SourceType Aggregation Database
Index Database
Publisher
StartPage 949
SubjectTerms Algorithms
Betacoronavirus
Cardiology
Coronavirus Infections - blood
Coronavirus Infections - complications
COVID-19
Fibrin Fibrinogen Degradation Products - analysis
Fibrinolytic Agents - therapeutic use
Humans
Liver Failure - therapy
Pandemics
Partial Thromboplastin Time
Platelet Count
Pneumonia, Viral - blood
Pneumonia, Viral - complications
Prothrombin Time
Review Article
Risk
SARS-CoV-2
Thrombophilia - prevention & control
Thrombophilia - therapy
Thrombosis - prevention & control
Thrombosis - therapy
Treatment Outcome
Title Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge
URI http://dx.doi.org/10.1055/s-0040-1710317
https://www.ncbi.nlm.nih.gov/pubmed/32349133
https://www.proquest.com/docview/2396854554
Volume 120
WOSCitedRecordID wos000538130700008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3JTsMwELXYhLiwL2WTkRC3iCReEnOrKqoeoEKoRb1ZjhfaQxOUtHw_4zQFBBy4WDnYUjyesWf8xvMQuva8J86FIshCk0GAEtlAacICpp3R1oVM1a_SXh6Sfj8djcTT133HTwSfsdsqqLPeosQTEiSraD0GLfUmGA75J17Aac2vEhKfzB5TtizP-Gv8X44kfMzGEzu1306W7s7__2kXbTfeI24vlnsPrdh8H20-Nvj4AXruQVhZ6kK9NqxcWOUGt_1T3HFZTLMCxuHBMrccT3Lc8RUM1PuknFcYTmlxh9sYNj7cWZKsHKJh937Q6QUNa0KgqaCzwDimlaPCWk5TRZwhNNOGu4jrJHJUG6JFpmJf99yBr8QM7HbORkZFEHolxJIjtJYXuT1BWIWZzcDILQstTYlTnBsneKwFzN4q1kJXS2FK0EoPNajcFvNKxkTwFJwzRlvoeCFl-bYonyFJTKiA0LiFbhZil43ZVLJGxBmTlfTylY18T__b8QxtxT4cri9JztHarJzbC7Sh32eTqrysNQbaZJRC2396_AAdAriy
linkProvider Thieme
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwEB7BgoAL70dZHkZC3KIm8SM1t6raVRHdCqEu2pvl2GNaiSarJN3fj504CGk57IFbDrFkfxmNZzLfzAfwMeieOJfKpExt6ROUDBNtKE-4cdagS7nuu9J-rIr1enZxIb_F9ug20iq77Q73mJjA9DBdoFpcDtNP2ylGhNvpttv_ijq1fNomPTMuK4JoQXEb7vCgIOGtOz0Xf2oKgvUaLCkNhPec8XGE47X1_wo2_cOwrb9un9NH_3ffj-FhjELJfDCbJ3ALq6dw7yzW2Z_B96VPTxtT659R3YvoypJ5aOndNvW-rP06shk56mRXkUWYhKCvds2hJf62l5_JnHgHShajWMtzOD892SyWSVRfSAyTrEus40Y7JhEFm2nqLGWlscJlwhSZY8ZSI0udh_npzsdc3Hqv6TCzOvMpXEGRvoCjqq7wFRCdllh6Z4E8RTajTgthnRS5kf70qPkEPoyAK2_doWShK6wPrcqpFDMf5HE2gZfDl1CXwxgORXPKpE-xJ_BpQF6NIKu-ss65alXAV0V8X9_0xfdwf7k5W6nVl_XXY3iQhxS7__HyBo665oBv4a656nZt8663sN9DUNa6
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB5RqFAvQB-0Wx51paq3dJP4kXVvq4UVqHSLKqi4WY49LnsgWSVZfj92HhVSOfTQW6Q8ZH0ejWcy38wH8CnonjgXyyiPbe4TlAQjbSiPuHHWoIu5brvSfl1ki8Xk5kZebsCPoRcm0Cqb2yXeYWQC08M0gWqx6qaf1mPsEa7HK-t6mVo-rqOWGJdkQbMg--JvPYMt7q0xaDnE1-JPWUGwVoYlpoHznjI-THH86xtPxZv-olvZowNovvvfl74HO30sSqad8byEDSxewfb3vtr-Gn6e-SS1MqX-3Wt8EV1YMg2NvbdVeZeX_j1yNTDVybIgszAPQd8vq3VN_Jkvv5Ip8W6UzAbJljdwPT-9mp1FvQZDZJhkTWQdN9oxiSjYRFNnKcuNFS4RJkscM5Yames0TFF3PvLi1vtOh4nViU_kMop0HzaLssB3QHScY-5dBvIY2YQ6LYR1UqRGegRQ8xF8HDBX3sZD4UIXWK5rlVIpJj7U42wEb7vNUKtuGIeiKWXSJ9oj-NyBrwacVVtf51zVKmCseozf_-uDH2D78mSuLs4X3w7gRRry7PbvyyFsNtUaj-C5uW-WdXXc2tgDnkbYNA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hypercoagulation+and+Antithrombotic+Treatment+in+Coronavirus+2019%3A+A+New+Challenge&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Violi%2C+Francesco&rft.au=Pastori%2C+Daniele&rft.au=Cangemi%2C+Roberto&rft.au=Pignatelli%2C+Pasquale&rft.date=2020-06-01&rft.pub=Georg+Thieme+Verlag+KG&rft.issn=0340-6245&rft.eissn=2567-689X&rft.volume=120&rft.issue=6&rft.spage=949&rft.epage=956&rft_id=info:doi/10.1055%2Fs-0040-1710317&rft.externalDBID=HTML_FULL_TEXT&rft.externalDocID=10_1055_s_0040_1710317
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon